Wanbury Peer Comparison

Snapshot Summary

Wanbury Ltd. exhibits strong revenue growth but struggles with profitability metrics due to a high debt equity ratio. In comparison to its peers, several companies outperform in profitability and valuation, with some showing signs of financial risk.

• Wanbury Ltd. shows significant YoY revenue growth at 15.21%.
• Highest EPS growth is with Divi's Laboratories Ltd. at 82.53.
• Dr. Reddy's Laboratories Ltd. leads in ROE at 21.76%.
• Cipla Ltd. is the most attractively valued based on PE and PBV ratios.
• Mankind Pharma Ltd. shows exceptional growth trajectory with 155.25% 3-year revenue growth.

• Mankind Pharma Ltd.: Highest 3-year revenue growth at 155.25% and strong profitability metrics.
• Dr. Reddy's Laboratories Ltd.: Leads in profitability with a ROE of 21.76% and a low PE ratio of 15.50.
• Cipla Ltd.: Best valuation metrics with a PE of 23.73 and strong profitability.

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
WANBURY	₹276.75	₹906.92Cr	29.80	101.15%	5.21
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Wanbury Peer Comparison

Snapshot Summary